» Articles » PMID: 38067255

Chimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 9
PMID 38067255
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial cell adhesion molecule (EpCAM) is a tumor-associated antigen that is frequently overexpressed in various carcinomas. We have developed chimeric antigen receptor (CAR) T cells specifically targeting EpCAM for the treatment of gastric cancer. This study sought to unravel the precise mechanisms by which tumors evade immune surveillance and develop resistance to CAR T cell therapy. Through a combination of whole-body CAR T cell imaging and single-cell multiomic analyses, we uncovered intricate interactions between tumors and tumor-infiltrating lymphocytes (TILs). In a gastric cancer model, tumor-infiltrating CD8 T cells exhibited both cytotoxic and exhausted phenotypes, while CD4 T cells were mainly regulatory T cells. A T cell receptor (TCR) clonal analysis provided evidence of CAR T cell proliferation and clonal expansion within resistant tumors, which was substantiated by whole-body CAR T cell imaging. Furthermore, single-cell transcriptomics showed that tumor cells in mice with refractory or relapsing outcomes were enriched for genes involved in major histocompatibility complex (MHC) and antigen presentation pathways, interferon- and interferon- responses, mitochondrial activities, and a set of genes (e.g., , , ) linked to tumor progression and unfavorable disease prognoses. This research highlights an approach that combines imaging and multiomic methodologies to concurrently characterize the evolution of tumors and the differentiation of CAR T cells.

Citing Articles

Targeting Hepatic Cancer Stem Cells (CSCs) and Related Drug Resistance by Small Interfering RNA (siRNA).

Jasim S, Omar Dheyauldeen Salahdin , Malathi H, Sharma N, Rab S, Aminov Z Cell Biochem Biophys. 2024; 82(4):3031-3051.

PMID: 39060914 DOI: 10.1007/s12013-024-01423-5.


Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.

Yang Y, Vedvyas Y, Alcaina Y, Son J, Min I, Jin M Front Immunol. 2024; 15:1355388.

PMID: 38550578 PMC: 10972862. DOI: 10.3389/fimmu.2024.1355388.

References
1.
Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J . Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. Immunity. 2020; 53(2):456-470.e6. DOI: 10.1016/j.immuni.2020.07.011. View

2.
Good C, Aznar M, Kuramitsu S, Samareh P, Agarwal S, Donahue G . An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. 2021; 184(25):6081-6100.e26. PMC: 8827167. DOI: 10.1016/j.cell.2021.11.016. View

3.
Liu Y, Yang J, Huang D, Ni H, Zhang C, Zhang L . Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways. Front Immunol. 2020; 11:1906. PMC: 7472844. DOI: 10.3389/fimmu.2020.01906. View

4.
Chinnasamy D, Yu Z, Kerkar S, Zhang L, Morgan R, Restifo N . Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res. 2012; 18(6):1672-83. PMC: 6390958. DOI: 10.1158/1078-0432.CCR-11-3050. View

5.
Srivastava S, Furlan S, Jaeger-Ruckstuhl C, Sarvothama M, Berger C, Smythe K . Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell. 2020; 39(2):193-208.e10. PMC: 7878409. DOI: 10.1016/j.ccell.2020.11.005. View